Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 3;9(3):87-102.
doi: 10.3727/215517916X693069. eCollection 2017.

A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Severe Buerger's Disease

Jeong Chan Ra  1 , Euicheol C Jeong  2   3 , Sung Keun Kang  1 , Seog Ju Lee  1 , Kyoung Ho Choi  1
Affiliations

A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Severe Buerger's Disease

Jeong Chan Ra et al. Cell Med. .

Abstract

Buerger's disease is a rare and severe disease affecting the blood vessels of the limbs. Adipose tissue-derived mesenchymal stem cells (ADSCs) have the potential to cure Buerger's disease when developed as a stem cell drug. In the present study, we conducted a prospective, nonrandomized, no placebo-controlled, phase I/II clinical trial with a 2-year follow-up questionnaire survey. A total of 17 patients were intramuscularly administered autologous ADSCs at a dose of 5 million cells/kg. The incidence of adverse events (AEs), adverse drug reaction (ADR), and serious adverse events (SAEs) was monitored. No ADRs and SAEs related to stem cell treatment occurred during the 6-month follow-up. In terms of efficacy, the primary endpoint was increase in total walking distance (TWD). The secondary endpoint was improvement in rest pain, increase in pain-free walking distance (PFWD), toe-brachial pressure index (TBPI), transcutaneous oxygen pressure (TcPO2), and arterial brachial pressure index (ABPI). ADSCs demonstrated significant functional improvement results including increased TWD, PFWD, and rest pain reduction. No amputations were reported during the 6-month clinical trial period and in the follow-up questionnaire survey more than 2 years after the ADSC injection. In conclusion, intramuscular injection of ADSCs is very safe and is shown to prompt functional improvement in patients with severe Buerger's disease at a dosage of 300 million cells per 60 kg of body weight. However, the confirmatory therapeutic efficacy and angiogenesis need further study.

Keywords: Adipose tissue; Autologous; Buerger’s disease; Mesenchymal stem cells (MSCs).

PubMed Disclaimer

Conflict of interest statement

E.C. Jeong declares no conflict of interest.

Figures

Figure 1
Figure 1
Patient disposition. ITT, intention to treat; mITT, modified intention to treat; PP, per protocol; TWD, total walking distance; N, number.
See this image and copyright information in PMC

References

    1. Olin JW, Shih A. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343:864–9. - PubMed
    1. Fiessinger JN. Buerger’s disease or thromboangiitis obliterans. In: Tooke JE, Lowe GDO, editors. A textbook of vascular medicine. London (ENG): Arnold; 1996. p. 275–86.
    1. Patel DM, Shah J, Srivastava AS. Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int. 2013;2013:496218. - PMC - PubMed
    1. Xi J, Yan X, Zhou J, Yue W, Pei X. Mesenchymal stem cells in tissue repairing and regeneration: Progress and future. Burns Trauma 2013;1:13–20. - PMC - PubMed
    1. Ishikawa T, Banas A, Hagiwara K, Iwaguro H, Ochiya T. Stem cells for hepatic regeneration: The role of adipose tissue derived mesenchymal stem cells. Curr Stem Cell Res Ther. 2010;5:182–9. - PubMed